THE DATA BEHIND OUR PRODUCTS
Jeffrey Gudin, M.D., Virpax’s Chief Medical Officer, has presented various posters on Virpax’s scientific advancements and discoveries.
A poster entitled “Enkephalin as a Potential Analgesic and CNS Modulator“ appeared at PAINWeek 2021. It shows that nanoparticle encapsulation of enkephalin would lead to effective brain delivery and analgesia.
Two other posters were presented at the 2019 Military Health System Research Symposium (MHSRS) on August 21, 2019:
The first poster, NSAID Topical Diclofenac Epolamine Spray Film Epoladerm for the Management of Acute Musculoskeletal Pain explains how the Virpax proprietary 12-hour topical metered-dose spray film formulation is being studied to manage acute musculoskeletal pain.
The second poster, Sustained Non-Opioid Pain Management in Prolonged Field Care and Hospital Settings Using Probudur describes how the company’s proprietary liposomal bupivacaine gel demonstrated the ability to provide post-operative pain control for up to 96 hours.